TITLE

Interaction Profile of Moxifloxacin

AUTHOR(S)
Stass, H.; Kubitza, D.
PUB. DATE
December 1999
SOURCE
Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p235
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Investigates the influence of probenecid on the elimination of moxifloxacin. Methods; Results.
ACCESSION #
9593518

 

Related Articles

  • Moxifloxacin.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p202 

    The article presents a case study of a 78-year-old male patient who developed acute confusional syndrome during moxifloxacin treatment.

  • Comparative In Vitro and In Vivo Activity of the C-8 Methoxy Quinolone Moxifloxacin and the C-8 Chlorine Quinolone BAY γ 3118. Dalhoff, Axel // Clinical Infectious Diseases;3/15/2001 Supplement 1, Vol. 32, pS16 

    The C-8 methoxy quinolone moxifloxacin is highly bactericidal against wild-type and first-step gyrase-and topoisomerase IV-resistant mutants. This finding led to the hypothesis that the C-8 methoxy group may lower the propensity for resistance development compared with quinolones possessing...

  • Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. Jürgen Barth; Doris Jäger; Ralf Mundkowski; Bernd Drewelow; Tobias Welte; Olaf Burkhardt // Journal of Antimicrobial Chemotherapy (JAC);Sep2008, Vol. 62 Issue 3, p575 

    : Objectives The aim of this study was to investigate the single- and multiple-dose pharmacokinetics (PK) of moxifloxacin and its penetration into ascitic fluid in patients with severe liver insufficiency (Child–Pugh class C). : Patients and methods In a single-centre, prospective,...

  • Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus. Hoang Anh Nguyen; Jean Grellet; Véronique Dubois; Marie-Claude Saux; Claudine Quentin // Journal of Antimicrobial Chemotherapy (JAC);Mar2007, Vol. 59 Issue 4, p755 

    Objectives The aim of this study was to determine the intracellular activity of moxifloxacin against a reference strain and a clinical strain and to study the factors compromising the intracellular activity of moxifloxacin. Methods The bactericidal activity of...

  • Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D. Jan Rupp; Werner Solbach; Jens Gieffers // Journal of Antimicrobial Chemotherapy (JAC);Jan2008, Vol. 61 Issue 1, p91 

    : Objectives Quinolone resistance of chlamydiae is supposed to be extremely rare. To assess the risk for the emergence of chlamydial quinolone resistance, we analysed the occurrence of resistant mutants in a quantitative perspective. : Methods Infectious elementary bodies of Chlamydia...

  • In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains. Violeta Rodríguez-Cerrato; Pedro García; Gema del Prado; Ernesto García; Matilde Gracia; Lorena Huelves; Carmen Ponte; Rubens López; Francisco Soriano // Journal of Antimicrobial Chemotherapy (JAC);Nov2007, Vol. 60 Issue 5, p1159 

    Objectives In an innovative therapeutic exploitation against antibiotic-resistant Streptococcus pneumoniae, here we have evaluated the in vitro activity of a purified bacterially-encoded cell wall lytic enzyme, LytA (the major pneumococcal autolysin), and compared it with those of Cpl-1 and Pal...

  • Moxifloxacin for Odontogenic Infection.  // Infectious Disease Alert;Nov2011, Vol. 31 Issue 2, p20 

    Outpatients with a diagnosis of either dentoalveolar or periodontal abscess or a diagnosis of gingival inflammatory infiltrates were randomized to receive either moxiloxacin 400 mg daily or clindamycin 300 mg QID, both for 5 days, in a prospective, randomized, placebo-controlled, double-dummy...

  • Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. Yoshida, Koichiro; Okimoto, Niro; Kishimoto, Michihiro; Fukano, Hiroshi; Hara, Hiroki; Yoneyama, Hirohide; Moriya, Osamu; Kawanishi, Masayoshi; Kimura, Makoto; Matsushima, Toshiharu; Niki, Yoshihito // Journal of Infection & Chemotherapy (Springer Science & Business;Oct2011, Vol. 17 Issue 5, p678 

    Moxifloxacin is a respiratory quinolone that is expected to be useful for treating community-acquired bacterial pneumonia, but few clinical studies and not a detailed evaluation of its pharmacokinetics have been conducted in Japan in patients with pneumonia. We assessed the efficacy and safety...

  • Development of a nanosomal formulation of moxifloxacin based on poly(butyl-2-cyanoacrylate). Shipulo, E.; Lyubimov, I.; Maksimenko, O.; Vanchugova, L.; Oganesyan, E.; Sveshnikov, P.; Biketov, S.; Severin, E.; Heifets, L.; Gel’perina, S. // Pharmaceutical Chemistry Journal;Mar2008, Vol. 42 Issue 3, p145 

    A nanosomal formulation of moxifloxacin has been prepared by anionic polymerization of poly(butyl-2-cyanoacrylate) in the presence of the drug. The poly(butyl-2-cyanoacrylate) nanoparticles absorb effectively moxifloxacin with a high total content and have a considerable capacity (> 45%). The...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics